INTRODUCTION

Biotech Open Platform has opened its French fermentation site to outside projects, according to Food Ingredients First and vegconomist. The move matters because scarce intermediate production capacity has constrained fermentation companies.

Danone, a food products group, established the platform in 2024 with Michelin, a tyre manufacturing group, and four regional and industrial partners, according to both publications. The partners have now inaugurated the site in Clermont-Ferrand, France. Vegconomist reports that its teams have begun handling the first advanced fermentation projects. Start-ups, industrial businesses and research bodies can apply to use the operation. Access does not depend on membership of the founding group.

The food case centres on helping developers move biological processes out of the laboratory without immediately paying for commercial manufacture. Food Ingredients First identifies proteins, enzymes and other fermentation-derived inputs as relevant targets. Vegconomist says limited access to larger facilities has repeatedly held back European developers. The platform therefore addresses a defined infrastructure gap. It does not settle whether a resulting ingredient will gain approval, work in a finished product or compete on cost. That distinction matters more than another large fermenter.

CORE FINDING

The central finding from both reports is that shared equipment can provide a bridge between laboratory work and commercial production. The site combines fermentation, downstream purification and bioprocess development, according to Food Ingredients First. Clients can use those functions to determine whether laboratory methods remain dependable under conditions closer to industrial manufacture. Khadidja Romari, chief executive of Biotech Open Platform, told both publications that machinery alone cannot solve the transfer problem. Staff also need practical experience and the ability to fix new faults as volumes rise. This is a service operation rather than spare tank capacity. Food Ingredients First concludes that the facility tackles only part of the route to market.

CAPACITY

The first phase represents an investment of €20 million, equal to US$22.7 million, according to Food Ingredients First. Vegconomist describes the total differently, reporting that spending has passed €20 million. That compares with a commitment above €16 million when the partners announced the project in June 2024, according to vegconomist. The two accounts do not conflict on the broad amount. One gives the stated first-phase figure, while the other says expenditure has moved beyond it. Food Ingredients First puts the building at 5,000 square metres. Its largest fermentation volume reaches 15 cubic metres, according to both publications. Food Ingredients First also says processes can begin with 10 grams and rise to one metric tonne of material. That range allows teams to examine several steps rather than attempt one abrupt jump from bench work to factory output.

PRODUCTION ROUTE

Vegconomist says users may work with yeast, bacteria, microalgae or fungi. Those organisms can make food inputs as well as proteins, enzymes, cosmetic actives and materials derived from biological feedstocks. The range gives the platform a wider remit than food alone. Developers first establish a biological process and then run it under conditions intended to resemble industrial production. Semi-industrial purification equipment separates the target material after fermentation, according to vegconomist. Process development teams can then adjust operating conditions and check whether output remains consistent. The operator claims that the installation meets standards used for food production, according to both publications. That claim concerns the facility. It does not amount to regulatory clearance for every substance produced inside it.

TESTING

The intermediate batches should give clients enough material for application trials before they commit to full manufacturing, according to both reports. This step matters because a substance that performs in a fermenter may still fail during formulation. Food Ingredients First reports that ingredient suppliers at Vitafoods Europe identified functionality, consistency and production volume as reasons to use fermentation. Those suppliers also named processing stability and shelf life as obstacles when biological inputs enter finished foods and drinks. A larger trial batch lets a developer examine those traits with real formulations. It can also reveal whether purification changes the ingredient or whether performance declines during storage. The reports provide no results from clients, so the platform’s practical effect on product development remains unproved.

GOVERNANCE

Biotech Open Platform uses its own workforce and infrastructure rather than operating through the staff of its shareholders, according to vegconomist. The separation aims to protect customer information and intellectual property. Romari told Food Ingredients First that confidentiality and ownership safeguards are essential for participating businesses. This structure matters when rival developers or large manufacturers use the same site. Shared production can lower the need for each client to build a dedicated pilot operation, but it also concentrates sensitive process knowledge in one organisation. The sources describe the safeguards in principle. They give no contractual terms, access prices, project timelines or rules for allocating equipment among clients.

FOUNDERS AND FUNDING

The other founders are DMC Biotechnologies, a US precision-fermentation manufacturer, Crédit Agricole Centre France, Clermont Auvergne Innovation and Greentech, a platform founding partner, according to both publications. Vegconomist says the European Regional Development Fund also supported the project through the Auvergne-Rhône-Alpes Region. Clermont Auvergne Métropole provided further backing, according to the same report. The facility sits inside the Sustainable Materials Center at Michelin’s Innovation Park, Cataroux, vegconomist reports. That mix of corporate, regional and European support spreads the cost of equipment that individual early-stage developers may struggle to justify. The counter-argument is that public and shared infrastructure does not prove customer demand. Neither report discloses booking levels, revenue, operating costs or the number of projects accepted.

PARTNER AIMS

The founders do not all seek food applications. Florent Menegaux, chairman of Michelin Group, told vegconomist that the tyre maker wants to test biological substitutes for some petrochemical molecules. DMC Biotechnologies makes nutraceutical ingredients and chemical intermediates through precision fermentation, according to vegconomist. Its chief executive, Jim Flatt, identifies the expense of proving a young process at larger volume as a central barrier. Danone has a different interest. Food Ingredients First says the group has previously linked the platform with new protein sources and other food inputs. These goals overlap at the level of fermentation engineering, even when the eventual products serve different markets. The shared asset can therefore spread its use across several sectors rather than depend on one class of ingredient.

EUROPEAN CONTEXT

Vegconomist says insufficient access to sizeable fermentation sites featured among market concerns raised around the EU Bioeconomy Strategy during the previous year. Food Ingredients First places the project within a broader rise in work on fermentation-derived vanillin, dairy cultures, precision-fermented proteins and manufacturing equipment. Those examples show that the relevant processes cover more than alternative protein. They also require different organisms, purification methods and quality controls. A flexible site may accommodate that variety, but the sources do not state which projects have entered its pipeline. Nor do they identify any cultivated-meat company as a customer. The direct relevance to cellular agriculture therefore lies in fermentation-enabled ingredients and production methods, not evidence of cultivated meat output at Clermont-Ferrand.

COMMERCIAL LIMITS

Food Ingredients First names cost, production yield, regulatory approval, ingredient function and compatibility with existing factories as unresolved barriers. Each test sits beyond the mere availability of a vessel. Low yield can leave a technically successful process too expensive. Regulatory review can delay market entry even when production works. A purified ingredient can also lose value if heat, acidity or storage damages its function. Existing food plants may require changes before they can use a novel input. DMC Biotechnologies argues that developers must show reliable and competitive production at larger volumes, according to vegconomist. That is the tougher standard. The platform can generate evidence for such a case, but neither source provides comparative production costs or successful commercial yields. Claims of faster industrialisation therefore come from the operator and its partners, not from disclosed client outcomes.

CONCLUSION

Danone chief executive Antoine de Saint-Affrique argues that shared infrastructure can strengthen Europe’s biotechnology base, according to Food Ingredients First. The platform deserves judgement by whether outside projects produce credible cost, performance and approval data, not by the size of its fermenters.